



November 2015

Porcine ex-vivo wound healing model

(Patent No. 10317400)



Generation of the wound healing model





Possibilities of modification:



- **Mode** and **time point** of application
- **Support** of the model with **nurients**
- **time point of evaluation**
- **infection**
- **customer requests**
- transfer to the human model for **selected** tests

Read out parameters

- **Wound healing progress**
Measurement of the regenerated epidermis
- **Wound margin morphology**
 - 0: macerated
 - 1: intermediate wound margin morphology
 - 2: very good wound margin morphology
- **proliferation rate** at the wound margins/in the regenerating epidermis
- **Number of apoptotic cells** at the wound margins/in the regenerating epidermis
- **barrier function**
- **expression of cytokines**
- **differentiation markers**
- **customer requests**



Good wound healing

Very good
preservation of
wound margin
(Score 2)




Bad wound healing

Macerated wound
margin (Score 0)



Example for the evaluation of wound healing progress



*: compared to untreated control

#: compared to placebo (Substance 1)

Literature

- Brandner JM, Houdek P, Quitschau T, Siemann-Harms U, Ohnemus U, Willhardt I, Moll I (2006) An Ex-vivo model to evaluate dressings & drugs for wound healing. Example: Influence of *Lucilia sericata* extracts on wound healing progress. ***EWMA J.*** 6: 11-15
- Brandner JM, Zacheja S, Houdek P, Moll I, Lobmann R (2008) Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. ***Diabetes Care*** 31(1): 114-120
- Ebeling S, Naumann K, Pollok S, Wardecki T, Vidal YSS, Nascimento JM, Boerries M, Schmidt G, Brandner JM, Merfort I (2014) From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. ***PLoS One*** 9(1): e86147
- Pollok S, Pfeiffer AC, Lobmann R, Wright CS, Moll I, Martin PE, Brandner JM (2011) Connexin 43 mimetic peptide Gap27 reveals potential differences in the role of Cx43 in wound repair between diabetic and non-diabetic cells. ***J Cell Mol Med*** 15(4): 861-873
- Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp HJ, Brandner JM (2011) Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. ***PLoS One*** 6(5): e19740
- Zubair M, Nybom H, Lindholm C, Brandner JM, Rumpunen K (2015) Promotion of wound healing by *Plantago major* L. leaf extracts - ex-vivo experiments confirm experiences from traditional medicine. ***Nat Prod Res***: 1-3

Interested?

Please call us or write an e-mail:

Prof. Dr. Johanna Brandner

Phone: +49-(0)40-7410-55819

Fax: +49-(0)40-7410-52655

e-mail: brandner@uke.de



Universitätsklinikum
Hamburg-Eppendorf

Why pig?



- Similar **Stratum corneum**
- **Percuteous absorption** very similar between man and pig
- Similar **morphology and histology**
- Many **antibodies** available for immunohistochemistry and immunoblot
- Identical **lokalisation** of the proteins

	pig	human
Ki-67	Prol. cells	Prol. cells
CK 1-10	++	++
CK 14	++	++
DPmix	++	++
Connexin 43, Cx 26 Mel 5	+ melanocytes	+ melanocytes
Occludin, Cl1, ZO-1 β-Catenin, Actin	++ ++	++ ++

- Possibility to perform **large test series**, because of good availability of larger amounts of tissue

- **Good reproducibility** between different individuals because:
 - same body location
 - same age
 - no underlying diseases
 - same processing from gain of tissue to model generation